No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation By Ogkologos - August 24, 2026 7 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SKYSCRAPER-03 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR TMB Consortium Develops a TMB Calibration Tool October 13, 2021 Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... January 21, 2021 Study Identifies Hundreds of Potential Targets for Cancer Drugs September 11, 2024 Black Women Have Nearly Three Times the Risk of Developing Triple... September 22, 2021 Load more HOT NEWS Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto
